Get the Stockscreener App
85.13
0.94%
-0.81
After Hours:
85.13
Vaxcyte Inc Stock (PCVX) Latest News
WCM Investment Management LLC Decreases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Vaxcyte (NASDAQ:PCVX) - MarketBeat
abrdn plc Increases Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Calamos Advisors LLC Lowers Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in Stock - MarketBeat
Vaxcyte advances to final stage in infant vaccine study - MSN
Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance
Jennison Associates LLC Buys 9,121 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
12 Best Healthcare Stocks to Buy According to Analysts - Insider Monkey
Vaxcyte SVP Mikhail Eydelman sells $450k in stock - MSN
Vaxcyte SVP Mikhail Eydelman sells $450k in stock By Investing.com - Investing.com Canada
Vaxcyte’s Promising Pipeline and Growth Potential Justifies Buy Rating - TipRanks
Vaxcyte advances to final stage in infant vaccine study By Investing.com - Investing.com Australia
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 - Yahoo Finance
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants - Clinical Trials Arena
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study - GlobeNewswire
Vaxcyte COO Jim Wassil sells $689,790 in stock - MSN
Vaxcyte Advances Phase 2 Study on Infant Pneumococcal Disease Prevention to Final Stage - Marketscreener.com
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention - The Bakersfield Californian
Revolutionary Pneumococcal Vaccine Shows Promise: Vaxcyte's VAX-31 Hits Major Clinical Milestone - StockTitan
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
Vaxcyte COO Jim Wassil sells $689,790 in stock By Investing.com - Investing.com Australia
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Vaccine Innovator Vaxcyte Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - GlobeNewswire Inc.
Nisa Investment Advisors LLC Raises Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
(PCVX) Proactive Strategies - Stock Traders Daily
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Brokers Set Expectations for Vaxcyte FY2025 Earnings - Defense World
Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Cantor Fitzgerald Predicts Vaxcyte FY2025 Earnings - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 By Investing.com - Investing.com South Africa
CARGO Therapeutics, Inc. Enters into Sublease Agreement with Vaxcyte, Inc -July 08, 2024 at 04:18 pm EDT - Marketscreener.com
Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market - MSN
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Insider Monkey
Vaxcyte (NASDAQ:PCVX) Trading Up 7.8%Should You Buy? - MarketBeat
Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):